MedTrace Logo

TheraSphere HUD For Treatment of Unresectable Hepatocellular Carcinoma (HCC)

NCT00683631 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 183

Last updated 2023-12-18

No results posted yet for this study

Summary

The purpose of this protocol is to provide access to Therasphere treatment for patients with liver tumors.

Conditions

Interventions

OTHER

TheraSphere HUD

TheraSphere is FDA approved under a Humanitarian Use Device. It is considered a brachytherapy device that delivers intra-arterial radiation therapy using yttrium-90 microspheres directly to liver tumors.

Sponsors & Collaborators

  • MDS Pharma Services

    collaborator INDUSTRY

  • University of Louisville

    lead OTHER

Principal Investigators

  • Robert C. Martin, MD · University of Louisville

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2004-01-31
Primary Completion
2021-04-01
Completion
2021-04-01

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00683631 on ClinicalTrials.gov